{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:34:34Z","timestamp":1791246874422,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.nbd.2015.03.023","type":"journal-article","created":{"date-parts":[[2015,4,6]],"date-time":"2015-04-06T07:27:56Z","timestamp":1428305276000},"page":"162-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"special_numbering":"C","title":["Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with \u03b1-synucleinopathies"],"prefix":"10.1016","volume":"78","author":[{"given":"R.T.","family":"Bartus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Kordower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"E.M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.R.","family":"Kruegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.L.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.E.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.W.","family":"Olanow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.D.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2015.03.023_bb0005","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/cne.10689","article-title":"Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects","volume":"461","author":"Ai","year":"2003","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.nbd.2015.03.023_bb0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.tins.2010.11.001","article-title":"Repairing the parkinsonian brain with neurotrophic factors","volume":"34","author":"Aron","year":"2011","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.nbd.2015.03.023_bb0015","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1146\/annurev.cellbio.042308.113313","article-title":"\u03b1-Synuclein: membrane interactions and toxicity in Parkinson's disease","volume":"26","author":"Auluck","year":"2010","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.nbd.2015.03.023_bb0020","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.nbd.2012.04.004","article-title":"Translating the therapeutic potential of neurotrophic factors to clinical \u2018proof of concept\u2019: a personal saga achieving a career-long quest","volume":"48","author":"Bartus","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2015.03.023_bb0040","series-title":"Proceedings of the 16th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT), Salt Lake City, UT","article-title":"CERE-120 (AAV2-NRTN) for the treatment of Parkinson's disease: experience from 4 clinical trials and human autopsy data","author":"Bartus","year":"2013"},{"key":"10.1016\/j.nbd.2015.03.023_bb0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/mds.23442","article-title":"Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains","volume":"26","author":"Bartus","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2015.03.023_bb0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neurobiolaging.2012.07.018","article-title":"Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating \u201cclinical proof-of-concept\u201d for AAV-neurturin (CERE-120) in Parkinson's disease","volume":"34","author":"Bartus","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.nbd.2015.03.023_bb0035","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/mt.2013.281","article-title":"Parkinson's disease gene therapy: success by design meets failure by efficacy","volume":"22","author":"Bartus","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2015.03.023_bb0045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0304-3940(99)00208-6","article-title":"Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry","volume":"265","author":"Braak","year":"1999","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.nbd.2015.03.023_bb0050","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.nbd.2006.08.021","article-title":"Age-associated increases of \u03b1-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease?","volume":"25","author":"Chu","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2015.03.023_bb0055","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/brain\/aws133","article-title":"Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease","volume":"135","author":"Chu","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2015.03.023_bb0060","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1523\/JNEUROSCI.5427-08.2009","article-title":"Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy","volume":"29","author":"Chung","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2015.03.023_bb0065","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.neuro.31.061307.090711","article-title":"Role of axonal transport in neurodegenerative diseases","volume":"31","author":"De Vos","year":"2008","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.nbd.2015.03.023_bb0080","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1093\/brain\/awr149","article-title":"GDNF fails to exert neuroprotection in a rat alpha-synuclein model of Parkinson's disease","volume":"134","author":"Decressac","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2015.03.023_bb0070","doi-asserted-by":"crossref","first-page":"163ra156","DOI":"10.1126\/scitranslmed.3004676","article-title":"Alpha-synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons","volume":"4","author":"Decressac","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.nbd.2015.03.023_bb0075","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.expneurol.2012.02.012","article-title":"Comparison of the behavioural and histological characteristics of the 6-OHDA and alpha-synuclein rat models of Parkinson's disease","volume":"235","author":"Decressac","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2015.03.023_bb0085","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000017069","article-title":"Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease","volume":"9","author":"Eriksdotter Jonhagen","year":"1998","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.nbd.2015.03.023_bb0090","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/sj.mt.6300010","article-title":"Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's Disease","volume":"15","author":"Gasmi","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2015.03.023_bb0095","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm850","article-title":"Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease","volume":"9","author":"Gill","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2015.03.023_bb0115","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/mds.21503","article-title":"Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys","volume":"22","author":"Herzog","year":"2007","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.nbd.2015.03.023_bb0105","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/mt.2008.170","article-title":"Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum","volume":"16","author":"Herzog","year":"2008","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.nbd.2015.03.023_bb0110","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1227\/01.NEU.0000340682.06068.01","article-title":"Expression, bioactivity, and safety 1year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease","volume":"64","author":"Herzog","year":"2009","journal-title":"Neurosurgery"},{"key":"10.1016\/j.nbd.2015.03.023_bb0100","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s13346-011-0037-z","article-title":"Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically-active neurotrophic factor proteins for neurodegenerative diseases","volume":"1","author":"Herzog","year":"2011","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.nbd.2015.03.023_bb0120","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1523\/JNEUROSCI.18-13-04929.1998","article-title":"Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons","volume":"18","author":"Horger","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2015.03.023_bb0125","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1523\/JNEUROSCI.22-07-02780.2002","article-title":"Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system","volume":"22","author":"Kirik","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2015.03.023_bb0135","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q","article-title":"Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease","volume":"46","author":"Kordower","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2015.03.023_bb0130","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ana.21032","article-title":"Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys","volume":"60","author":"Kordower","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2015.03.023_bb0140","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1093\/brain\/awt192","article-title":"Disease duration and the integrity of the nigrostriatal system in Parkinson's disease","volume":"136","author":"Kordower","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2015.03.023_bb0145","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.20737","article-title":"Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease","volume":"59","author":"Lang","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2015.03.023_bb0155","doi-asserted-by":"crossref","first-page":"10813","DOI":"10.1073\/pnas.152339799","article-title":"Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease","volume":"99","author":"Lo Bianco","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2015.03.023_bb0150","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.nbd.2004.06.008","article-title":"Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease","volume":"17","author":"Lo Bianco","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2015.03.023_bb0160","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm0705-703","article-title":"Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain","volume":"11","author":"Love","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2015.03.023_bb0170","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","article-title":"Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial","volume":"7","author":"Marks","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2015.03.023_bb0165","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2015.03.023_bb0175","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1089\/hum.2011.220","article-title":"Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease","volume":"23","author":"Mittermeyer","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.nbd.2015.03.023_bb0180","doi-asserted-by":"crossref","first-page":"12776","DOI":"10.1523\/JNEUROSCI.3463-09.2009","article-title":"Axonal transport defects in neurodegenerative diseases","volume":"29","author":"Morfini","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2015.03.023_bb0185","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0301-0082(98)00059-8","article-title":"Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases","volume":"57","author":"Mufson","year":"1999","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.nbd.2015.03.023_bb0190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1212\/WNL.60.1.69","article-title":"Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD","volume":"60","author":"Nutt","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2015.03.023_bb0200","article-title":"Neurturin gene delivery in Parkinson's disease: a double-blind controlled trial","author":"Olanow","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2015.03.023_bb0195","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5607\/en.2010.19.3.115","article-title":"The role of axonopathy in Parkinson's disease","volume":"19","author":"O'Malley","year":"2010","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.nbd.2015.03.023_bb0205","first-page":"94","article-title":"Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial)","volume":"40","author":"Penn","year":"1997","journal-title":"Neurosurgery"},{"key":"10.1016\/j.nbd.2015.03.023_bb0210","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.nurt.2008.02.003","article-title":"Treatment of Parkinson's disease with trophic factors","volume":"5","author":"Peterson","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nbd.2015.03.023_bb0220","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.1068613","article-title":"Axonal self-destruction and neurodegeneration","volume":"296","author":"Raff","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.nbd.2015.03.023_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2013.09.004","article-title":"A phase 2 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease","author":"Rafii","year":"2014","journal-title":"Alzheimer\u2019s Dement."},{"key":"10.1016\/j.nbd.2015.03.023_bb0225","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00401-004-0952-x","article-title":"Axonal transport defects: a common theme in neurodegenerative diseases","volume":"109","author":"Roy","year":"2005","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2015.03.023_bb0230","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.expneurol.2006.07.015","article-title":"Point source concentration of GDNF may explain failure of phase II clinical trial","volume":"202","author":"Salvatore","year":"2006","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2015.03.023_bb0235","doi-asserted-by":"crossref","first-page":"8083","DOI":"10.1523\/JNEUROSCI.1091-10.2010","article-title":"A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration","volume":"30","author":"Scott","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2015.03.023_bb0240","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.20861","article-title":"Crossroads in GDNF therapy for Parkinson's disease","volume":"21","author":"Sherer","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2015.03.023_bb0245","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3171\/jns.2005.102.2.0216","article-title":"Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor","volume":"102","author":"Slevin","year":"2005","journal-title":"J. Neurosurg."},{"issue":"Suppl. 1","key":"10.1016\/j.nbd.2015.03.023_bb0250","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1002\/mds.22639","article-title":"Clues to how alpha-synuclein damages neurons in Parkinson's disease","volume":"25","author":"Sulzer","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2015.03.023_bb0255","first-page":"1","article-title":"A phase I clinical trial of nerve growth factor gene therapy for Alzheimer disease","author":"Tuszynski","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2015.03.023_bb0260","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0006-8993(98)00131-0","article-title":"Expression of the proto-oncogene Ret, a component of the GDNF receptor complex, persists in human substantia nigra neurons in Parkinson's disease","volume":"792","author":"Walker","year":"1998","journal-title":"Brain Res."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996115000959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996115000959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T00:33:21Z","timestamp":1566520401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996115000959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":52,"alternative-id":["S0969996115000959"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2015.03.023","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with \u03b1-synucleinopathies","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2015.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}